Sp188
PROGNOSTICATION OF DISEASE COURSE IN IBD: THE PRESENT AND THE FUTURE
Date
May 18, 2024
Presenter
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
Tracks
Related Products
THE EFFECT OF NLRX1 ACTIVATION ON EOSINOPHILS IN ULCERATIVE COLITIS AND INFLAMMATION: TRANSLATIONAL LEARNINGS ACROSS DISEASES AND FROM MOUSE TO HUMAN
Background: Although the precise role of eosinophils in IBD is debated, elevated eosinophils may influence response to therapy and clinical outcomes1. Thus, therapeutic agents which affect both neutrophil and eosinophil recruitment may provide more robust clinical improvement in patients with UC…
NEUTROPHIL EXTRACELLULAR TRAPS ENHANCE PROFIBROTIC ACTIVITY OF INTESTINAL FIBROBLASTS IN CROHN’S DISEASE THROUGH TLR2/NF-KB PATHWAY
BACKGROUND: Neutrophil extracellular traps (NETs) consist of DNA filaments and cytoplasmic protein granules, extruded by neutrophils after PAD4-dependent activation…
DISEASE CLEARANCE AFTER 16 WEEKS OF TREATMENT WITH VEDOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM THE VERDICT TRIAL
BACKGROUND: Disease clearance in ulcerative colitis (UC) is defined as concurrent achievement of clinical, endoscopic, and histologic remission…
EFFICACY AND SAFETY OF THE ORAL SELECTIVE SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR MODULATOR VTX002 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL
BACKGROUND: VTX002 is a novel oral selective sphingosine-1-phosphate-1 (S1P1) receptor modulator in development for the treatment of ulcerative colitis (UC)…
